Mp71-20 the prevalence of müllerian anomalies in females with a diagnosed renal anomaly

INTRODUCTION AND OBJECTIVE: The association between Wolffian and Mullerian anomalies has been previously established. Prior studies cite a prevalence of renal anomalies (RA) in 29-100% of patients previously diagnosed with Mullerian Anomalies (MA). However, the prevalence of MA among patients diagnosed with RA remains poorly defined, with estimates ranging from 30-70%. We sought to identify the prevalence of MA among patients with any RA and to determine the types of MA occurring in subgroups of RA. METHODS: We performed an IRB-approved, single-center, retrospective chart review of patients diagnosed with RA from 2007-2019. Demographic data was collected and the type of RA or MA was sub-classified, in addition to other anomalies. Descriptive statistics and Chi-squared analyses were performed. RESULTS: A total of 5590 cases of possible RA were then identified, from which a sample of 288 cases were identified. A subset of 188 patients was confirmed to have RA. Mean length of follow-up was 10.8+/-6.75 years. Mean age at diagnosis of RA was earlier (2.53 + 4.98 years) than MA (8.61 + 6.66 years). Of patients receiving an initial diagnosis of RA, the prevalence of any MA was 37.8% (71/188). Patients who had undergone menarche were significantly more likely to be diagnosed with a MA (p < 0.0001). MA was most often identified in patients with unilateral renal agenesis (41/71, 57.7%). Of 104 patients with renal agenesis, 14.4% (15 patients) were found to have OHVIRA syndrome, 11.5% (12 patients) were found to have uterine didelphys, and 13.5% (14 patients) had other MA (Table 1). CONCLUSIONS: Our pilot study demonstrates a high prevalence of MA (37.8%) among patients with RA, most commonly associated with renal agenesis. These findings suggest that patients with RA, especially renal agenesis, warrant preemptive, pre-menarchal screening for MA. Larger scale studies will be needed to determine the true incidence of MA among patients with RA.Source of Funding: None.